• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Relation of Venous Thromboembolism Risk to Ischemic Stroke Risk in Hospitalized Patients with Cancer
Patients with cancer are at increased risk for venous thromboembolism (VTE). However, the relationship of cancer type to the risk of arterial thrombosis in patients with high VTE risk has not been described. The goal of this study is to determine the rate of arterial thrombosis in patients with different types of solid tumors stratified by VTE risk. Using the 2012 National Inpatient Sample, we identified 373,789 hospitalizations involving patients ≥18 years associated with solid tumors, stratified by type.
Source: The American Journal of Cardiology - November 24, 2018 Category: Cardiology Authors: Alyssa M. Corley, Malachy J. Sullivan, Scott E. Friedman, Daniel J. O'Rourke, Robert T. Palac, Anthony S. Gemignani Source Type: research

Procedural and Short-Term Outcomes of Percutaneous Left Atrial Appendage Closure in Patients with Cancer
Percutaneous left atrial appendage closure (LAAC) with the Watchman device (Boston Scientific) has emerged as an alternative to anticoagulation in patients with atrial fibrillation (AF). Cancer is a common comorbidity in patients with AF (1,2). Also, AF patients with cancer reportedly have a higher bleeding risk with a similar or higher stroke risk than those without cancer (3). Thus, AF patients with cancer unsuitable for anticoagulation can be indicated for LAAC to prevent AF-related thromboembolism (2).
Source: The American Journal of Cardiology - December 3, 2020 Category: Cardiology Authors: Toshiaki Isogai, Anas M. Saad, Abdelrahman Ibrahim Abushouk, Shashank Shekhar, Shunsuke Kuroda, Mohamed M. Gad, Oussama M. Wazni, Amar Krishnaswamy, Samir R. Kapadia Source Type: research

Trends in Cardiovascular Mortality in Patients With Atrial Fibrillation and Cancer in the United States (1999 to 2020)
Cancer has been identified as an independent risk factor for atrial fibrillation (AF). Although the development of novel therapeutic agents has led to significant improvement in cancer-related outcomes, there is also a rising concern regarding the long-term impact of treatment-emergent cardiac adverse events such as AF.1 AF portends a poor prognosis in patients with cancer and is also associated with a twofold increase in the risk of stroke as compared with patients with AF without cancer.2 However, population-level data on the impact of AF on overall cardiovascular mortality in patients with cancer remain limited.
Source: The American Journal of Cardiology - August 19, 2023 Category: Cardiology Authors: Aakash R. Sheth, Udhayvir S. Grewal, Sahith R. Thotamgari, Harsh P. Patel, Paari Dominic Tags: Brief Report Source Type: research

Pages: 1  2